نتائج البحث - "Kuss, I"

1

Academic Journal

Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

المؤلفون: Jones, RH, Fizazi, K, James, ND, Tammela, TL, Matsubara, N, Priou, F, Beuzeboc, P, Lesimple, T, Bono, P, Kataja, V, Garcia, JA, Protheroe, A, Shore, N, Aspegren, J, Joensuu, H, Kuss, I, Fiala-Buskies, S, Vjaters, E

الاتاحة: https://doi.org/10.1038/s41391-023-00740-9
https://ora.ox.ac.uk/objects/uuid:308193a3-8701-49b2-97a1-182b2610805f

View record in BASE

2

Electronic Resource

PSA-Ansprechen unter Darolutamid (DARO) oder Placebo (PBO) + Androgen-Deprivationstherapie (ADT)/Docetaxel (DOC) bei Patienten mit high- und low-volume metastasiertem hormonsensitivem Prostatakrebs (mHSPC) in ARASENS

المؤلفون: Goebell, PJ, Saad, F, Hussain, M, Tombal, B, Fizzazi, K, Sternberg, CN, Crawford, ED, Bögemann, M, Tutrone, RF, Littleton, N, Srinivasan, S, Verholen, F, Kuss, I, Smith, MR

المصدر: 50. Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie; 20240502-20240504; München; DOC24urobay32 /20240426/

مصطلحات الفهرس: ddc: 610, conferenceObject

URL: http://nbn-resolving.de/urn:nbn:de:0183-24urobay327
http://www.egms.de/en/meetings/urobay2024/24urobay32.shtml

View record in OAIster

3

Electronic Resource

Prostataspezifisches Antigen (PSA)-Ergebnisse unter Darolutamid (DARO) oder Placebo, Androgen-Deprivationstherapie (ADT) und Docetaxel (DOC) bei Patienten mit high- und low-volume metastasiertem hormonsensitivem Prostatakrebs (mHSPC) in ARASENS

المؤلفون: Gratzke, C, Saad, F, Hussain, M, Tombal, B, Fizazi, K, Sternberg, C, Crawford, D, Boegemann, M, Tutrone, R, Littleton, N, Srinivasan, S, Verholen, F, Kuss, I, Smith, M

المصدر: 64. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V.; 20240619-20240622; Freiburg; DOCV5.7 /20240513/

مصطلحات الفهرس: ddc: 610, conferenceObject

URL: http://nbn-resolving.de/urn:nbn:de:0183-24swdgu477
http://www.egms.de/en/meetings/swdgu2024/24swdgu47.shtml

View record in OAIster

4

Academic Journal

173P Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)

المؤلفون: Parnis, F., Tombal, B., Hussain, M., Saad, F., Fizazi, K., Sternberg, C.N., Crawford, E.D., Kopyltsov, E., Rezazadeh Kalebasty, A., Alekseev, B.Y., Montesa Pino, A., Ye, D., Melo Cruz, F.J.S., Tammela, T., Suzuki, H., Joensuu, H., Thiele, S., Li, R., Kuss, I., Smith, M.

المصدر: Annals of Oncology ; volume 33, page S1501-S1502 ; ISSN 0923-7534

الاتاحة: http://dx.doi.org/10.1016/j.annonc.2022.10.210
https://api.elsevier.com/content/article/PII:S0923753422044015?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0923753422044015?httpAccept=text/plain

View record in BASE

5

Academic Journal

1360MO Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study

المؤلفون: Fizazi, K., Smith, M.R., Hussain, M., Saad, F., Sternberg, C., Crawford, E.D., Aragon-Ching, J.B., Thiele, S., Kapur, S., Mohamed, A.F., Srinivasan, S., Li, R., Kuss, I., Joensuu, H., Tombal, B.

المصدر: Annals of Oncology ; volume 33, page S1162 ; ISSN 0923-7534

الاتاحة: http://dx.doi.org/10.1016/j.annonc.2022.07.1492
https://api.elsevier.com/content/article/PII:S0923753422033439?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0923753422033439?httpAccept=text/plain

View record in BASE

6

Report

Gauge-Boson Pair Production at the LHC: Anomalous Couplings and Vector-Boson Scattering

المؤلفون: Kuss, I., Nuss, E.

المصدر: Eur.Phys.J.C4:641-660,1998

مصطلحات موضوعية: High Energy Physics - Phenomenology

URL الوصول: http://arxiv.org/abs/hep-ph/9706406

View record in Arxiv

7

Report

A Simple Approximation of the One-Loop Corrected Cross Section for $e^+e^-\to W^+W^-$ at LEP 2

المؤلفون: Kuroda, M., Kuss, I., Schildknecht, D.

المصدر: Phys.Lett. B409 (1997) 405-411

مصطلحات موضوعية: High Energy Physics - Phenomenology

URL الوصول: http://arxiv.org/abs/hep-ph/9705294

View record in Arxiv

8

Report

Improved Effective Vector-Boson Approximation for Hadron-Hadron Collisions

المؤلفون: Kuss, I.

المصدر: Phys.Rev.D55:7165-7182,1997

مصطلحات موضوعية: High Energy Physics - Phenomenology

URL الوصول: http://arxiv.org/abs/hep-ph/9608453

View record in Arxiv

9

Report

Discovering Non-Abelian Weak Couplings and an Anomalous Magnetic Dipole Moment of the $W^{\pm}$ at LEP~2

المؤلفون: Kuss, I., Schildknecht, D.

المصدر: Phys.Lett. B383 (1996) 470-474

مصطلحات موضوعية: High Energy Physics - Phenomenology

URL الوصول: http://arxiv.org/abs/hep-ph/9603283

View record in Arxiv

10

Report

Luminosities for Vector-Boson Vector-Boson Scattering at High Energy Colliders

المؤلفون: Kuss, I., Spiesberger, H.

المصدر: Phys.Rev.D53:6078-6093,1996

مصطلحات موضوعية: High Energy Physics - Phenomenology

URL الوصول: http://arxiv.org/abs/hep-ph/9507204

View record in Arxiv

11

Report

On Non-Standard Couplings among the Electroweak Vector Bosons

المؤلفون: Grosse-Knetter, C., Kuss, I., Schildknecht, D.

المصدر: Phys.Lett. B358 (1995) 87-94

مصطلحات موضوعية: High Energy Physics - Phenomenology

URL الوصول: http://arxiv.org/abs/hep-ph/9506472

View record in Arxiv

12

Academic Journal

222P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial

المؤلفون: Smith, M.R., Shore, N.D., Tammela, T.L.J., Berre, M-A. Le, Petrenciuc, O., Zurth, C., Kuss, I., Fizazi, K.

المساهمون: Bayer Corporation

المصدر: Annals of Oncology ; volume 31, page S1327-S1328 ; ISSN 0923-7534

الاتاحة: http://dx.doi.org/10.1016/j.annonc.2020.10.442
https://api.elsevier.com/content/article/PII:S0923753420429333?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0923753420429333?httpAccept=text/plain

View record in BASE

13

Academic Journal

223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

المؤلفون: Fizazi, K., Shore, N.D., Tammela, T.L.J., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Berre, M-A. Le, Petrenciuc, O., Snapir, A., Sarapohja, T., Smith, M.R.

المساهمون: Bayer

المصدر: Annals of Oncology ; volume 31, page S1328 ; ISSN 0923-7534

الاتاحة: http://dx.doi.org/10.1016/j.annonc.2020.10.443
https://api.elsevier.com/content/article/PII:S0923753420429345?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0923753420429345?httpAccept=text/plain

View record in BASE

14

Academic Journal

633P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial

المؤلفون: Fizazi, K., Shore, N., Smith, M.R., Tammela, T.L., Le Berre, M-A., Petrenciuc, O., Zurth, C., Kuss, I.

المصدر: Annals of Oncology ; volume 31, page S522 ; ISSN 0923-7534

الاتاحة: http://dx.doi.org/10.1016/j.annonc.2020.08.892
https://api.elsevier.com/content/article/PII:S0923753420408889?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0923753420408889?httpAccept=text/plain

View record in BASE

15

Academic Journal

Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) >6 months

المؤلفون: Bögemann, M.W.H., Shore, N.D., Tammela, T.L.J., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Le Berre, M-A., Snapir, A., Sarapohja, T., Fizazi, K.

المصدر: European Urology Open Science ; volume 19, page e1389-e1390 ; ISSN 2666-1683

الاتاحة: http://dx.doi.org/10.1016/s2666-1683(20)33516-3
https://api.elsevier.com/content/article/PII:S2666168320335163?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S2666168320335163?httpAccept=text/plain

View record in BASE

16

Electronic Resource

Dosierung, Sicherheit und Pharmakokinetik der Kombinationstherapie mit Darolutamid (DARO), Androgendeprivationstherapie (ADT) und Docetaxel (DOC) bei Patienten mit metastasiertem hormonsensitivem Prostatakarzinom (mHSPC) in der ARASENS Studie

المؤلفون: Rausch, S, Rezazadeh Kalebasty, A, Tombal, B, Hussain, M, Saad, F, Fizazi, K, Sternberg, C, Crawford, E, Kapur, S, Zhang, W, Ploeger, B, Li, R, Kuss, I, Zieschang, C, Wittemer-Rump, S, Smith, M

المصدر: 63. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V.; 20230621-20230624; Reutlingen; DOCV5.9 /20230620/

مصطلحات الفهرس: ddc: 610, conferenceObject

URL: http://nbn-resolving.de/urn:nbn:de:0183-23swdgu0481
http://www.egms.de/en/meetings/swdgu2023/23swdgu048.shtml

View record in OAIster

17

Electronic Resource

Effizienz und Sicherheit von Darolutamid (DARO) in Kombination mit Androgendeprivationstherapie (ADT) und Docetaxel (DOC) nach Krankheitsvolumen und -risiko in der Phase 3 ARASENS Studie

المؤلفون: Gratzke, C, Hussain, M, Tombal, B, Saad, F, Fizazi, K, Sternberg, C, Crawford, E, Shore, N, Kopyltsov, E, Rezazadeh Kalebasty, A, Bögemann, M, Ye, D, Cruz, F, Suzuki, H, Kapur, S, Srinivasan, S, Verholen, F, Kuss, I, Joensuu, H, Smith, M

المصدر: 63. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V.; 20230621-20230624; Reutlingen; DOCV5.6 /20230620/

مصطلحات الفهرس: ddc: 610, conferenceObject

URL: http://nbn-resolving.de/urn:nbn:de:0183-23swdgu0450
http://www.egms.de/en/meetings/swdgu2023/23swdgu045.shtml

View record in OAIster

18

Electronic Resource

Lebensqualität und Patienten-relevante Endpunkte unter Darolutamid-Therapie in der Phase-3-Studie ARASENS

المؤلفون: Todenhöfer, T, Fizazi, K, Smith, M, Hussain, M, Saad, F, Sternberg, C, Crawford, E, Aragon-Ching, J, Silke, T, Kapur, S, Mohamed, A, Srinivasan, S, Li, R, Kuss, I, Joensuu, H, Tombal, B

المصدر: 63. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V.; 20230621-20230624; Reutlingen; DOCV5.7 /20230620/

مصطلحات الفهرس: ddc: 610, conferenceObject

URL: http://nbn-resolving.de/urn:nbn:de:0183-23swdgu0461
http://www.egms.de/en/meetings/swdgu2023/23swdgu046.shtml

View record in OAIster

19

Academic Journal

Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial

المؤلفون: Pang, J.S.-T., Shore, N., Smith, M.R., Tammela, T.L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Le Berre, M.-A., Snapir, A., Sarapohja, T., Fizazi, K.

المصدر: Annals of Oncology ; volume 30, page ix69 ; ISSN 0923-7534

الاتاحة: http://dx.doi.org/10.1093/annonc/mdz424.001
https://api.elsevier.com/content/article/PII:S0923753419578796?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0923753419578796?httpAccept=text/plain
http://academic.oup.com/annonc/article-pdf/30/Supplement_9/mdz424.001/31094006/mdz424.001.pdf

View record in BASE

20

Academic Journal

1784P Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS

المؤلفون: Saad, F., Hussain, M., Tombal, B., Fizazi, K., Sternberg, C.N., Crawford, E.D., Boegemann, M., Tutrone, R., Littleton, N., Srinivasan, S., Verholen, F., Kuss, I., Smith, M.R.

المصدر: Annals of Oncology ; volume 34, page S964 ; ISSN 0923-7534

الاتاحة: http://dx.doi.org/10.1016/j.annonc.2023.09.2734
https://api.elsevier.com/content/article/PII:S0923753423035718?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0923753423035718?httpAccept=text/plain

View record in BASE

تنقيح النتائج